Research Team for Promoting Independence and Mental Health, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.
Niigata University of Pharmacy and Medical and Life Sciences Faculty of Medical Technology Department of Medical Technology, Niigata, Japan.
Eur Geriatr Med. 2024 Apr;15(2):571-577. doi: 10.1007/s41999-023-00914-7. Epub 2024 Jan 12.
This pilot study compared serum metabolites in participants with and without sarcopenia.
Metabolomic techniques were applied to identify serum metabolites and novel biomarkers specific to patients with sarcopenia. In accordance with AWGS2019 criteria, sarcopenia was defined as low muscle mass plus either low muscle strength/low physical function, and severe sarcopenia was defined as low muscle mass, low muscle strength, and low physical function all together.
The sarcopenia group had higher hypoxanthine, galactose, and mannose levels but lower triethanolamine and homogentisic acid levels than the non-sarcopenia group. The severe sarcopenia group had lower levels of alpha-tocopherol than the mild and moderate sarcopenia groups.
This study is the first to identify hypoxanthine as a potential biomarker for sarcopenia in humans and provides new insights into the pathophysiology of sarcopenia. Furthermore, the identified metabolites may be useful for the early detection of sarcopenia.
本初步研究比较了肌少症患者和非肌少症患者的血清代谢物。
应用代谢组学技术鉴定肌少症患者特有的血清代谢物和新型生物标志物。根据 AWGS2019 标准，肌少症定义为低肌肉量加上低肌肉力量/低身体功能，严重肌少症定义为低肌肉量、低肌肉力量和低身体功能全部存在。
与非肌少症组相比，肌少症组的次黄嘌呤、半乳糖和甘露糖水平较高，而三乙醇胺和高香草酸水平较低。严重肌少症组的α-生育酚水平低于轻度和中度肌少症组。
本研究首次鉴定出次黄嘌呤是人类肌少症的潜在生物标志物，并为肌少症的病理生理学提供了新的见解。此外，所鉴定的代谢物可能有助于肌少症的早期检测。
